Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

94P - CD44v6: A potential therapeutic target for liver carcinoma

Date

15 Oct 2022

Session

Poster display session

Presenters

Akshaya Srikanth

Citation

Annals of Oncology (2022) 33 (suppl_8): S1383-S1430. 10.1016/annonc/annonc1095

Authors

A. Srikanth1, A. Lechel1, K. Dembowsky2, R. Schirmbeck1

Author affiliations

  • 1 Ulm University Hospital, Internal Medicine I, Ulm/DE
  • 2 amcure GmbH, Eggenstein-Leopoldshafen/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 94P

Background

Liver cancer has a poor prognosis predominantly resulting from tumour heterogeneity and limited treatment options. The two predominant types of liver cancer are Hepatocellular carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (iCCA). CD44v6, a splice variant of the hyaluronic acid receptor CD44, is a marker for cancer stem cells, and is known to impact tumour formation and metastasis in several cancers. The expression of CD44v6 dramatically increases in liver epithelial cells upon carcinogen exposure. With this study, we aim to target CD44v6 in primary human liver carcinoma cell lines by using a small peptide inhibitor, and observe the effects of CD44v6 inhibition on migration, invasion and EMT.

Methods

CD44v6 expression was investigated in mouse and human liver and tumour tissue by immunohistochemistry. In addition, we used human HCC and CC cell lines to study the role of CD44v6 inhibition on cell migration, invasion and EMT.

Results

We observed CD44v6+ epithelial cells in premalignant livers of transgenic mouse models with chronic liver damage. The expression patterns of CD44v6+ cells differed in the mouse models, where the cells had a hepatocyte-like phenotype in some mouse models and a cholangiocyte-like phenotype in others. Deletion of Trp53 in the liver resulted in a significant increase in the number of CD44v6+ cells. CD44v6 expression was also increased in murine and human tumours compared to the liver, and coincided with Sox9 expression in murine tumours. Human liver cancer cell lines were analysed for CD44 expression and two CC cell lines were found to have high expression of CD44 (85-90%). Functional assays (clonogenic assay, wound healing assay and transwell migration assay) were performed using the CC cell lines. Treatment with AMC303 conferred a reduction in the migration potential of cells in CC cell lines. Inhibition of CD44v6 also resulted in a reduction in the colony formation potential of the cells, indicating a decrease in the stemness characteristics of the cells. A reduction in EMT in both 2D and 3D culture was also observed.

Conclusions

Inhibition of CD44v6 in liver cancer cell lines led to a reduction in chemotaxis, migration, EMT and the stemness characteristics of cells. In summary, CD44v6 appears to be a promising targetable candidate for liver carcinoma.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.